Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 1;207(3):493-6.
doi: 10.1093/infdis/jis710. Epub 2012 Nov 29.

Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series

Gregory A Raczniak  1 , Lisa R Bulkow, Michael G Bruce, Carolyn L Zanis, Richard L Baum, Mary M Snowball, Kathy K Byrd, Umid M Sharapov, Thomas W Hennessy, Brian J McMahon
Affiliations

Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series

Gregory A Raczniak et al. J Infect Dis. .

Abstract

The Centers for Disease Control and Prevention recommends hepatitis A virus (HAV) vaccination for all children at age 1 year and for high-risk adults. The vaccine is highly effective; however, protection duration is unknown. We report HAV antibody concentrations 17 years after childhood immunization, demonstrating that protective antibody levels remain and have stabilized over the past 7 years.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Geometric mean concentrations of antibody to hepatitis A virus (anti-HAV) in Alaska Native volunteers over time, by vaccine schedule. These graphs depict all available data for each time point. The large graph shows data from years 10–17 after receipt of the final dose, whereas the inset graph shows anti-HAV levels over the entire study period.
See this image and copyright information in PMC

References

    1. Bulkow LR, Wainwright RB, McMahon BJ, Middaugh JP, Jenkerson SA, Margolis HS. Secular trends in hepatitis A virus infection among Alaska Natives. J Infect Dis. 1993;168:1017–20. - PubMed
    1. Peach D, McMahon BJ, Bulkow L, Funk E, Harpaz R, Margolis HS. Impact of recurrent epidemics of hepatitis a virus infection on population immunity levels: Bristol Bay, Alaska. J Infect Dis. 2002;186:1081–5. - PubMed
    1. McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med. 1996;150:733–9. - PubMed
    1. Hammitt LL, Bulkow L, Hennessy TW, et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis. 2008;198:1776–82. - PubMed
    1. Byrd KK, Bruden DL, Bruce MG, et al. Long-term immunogenicity of inactivated hepatitis A vaccine: Follow-up at 15 years. J Pediatr Infect Dis. 2010;5:321–7.

Publication types

Substances